All In Biotech

Drugs by condition

Drugs approved for primary biliary cholangitis

Brand-name prescription drugs and biologics whose FDA label lists primary biliary cholangitis as an approved use. Matched on the label phrases: "primary biliary cholangitis".

Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

3

Still marketed, NDA or BLA

Drug classes

3

Novel drugs

3

New molecular entities and new biologics

In development

3

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for primary biliary cholangitis.

  • Lynavoy (Linerixibat) · Intercept NovelOrphanMar 17, 2026
  • Livdelzi (Seladelpar Lysine) · Gilead Sciences INC NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanAug 14, 2024
  • Iqirvo (Elafibranor) · Ipsen NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanJun 10, 2024

All approved drugs for primary biliary cholangitis, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 4 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Ileal Bile Acid Transporter Inhibitor (1)

  • Lynavoy Linerixibat · Intercept · 2026

Peroxisome Proliferator-activated Receptor Agonist (1)

  • Iqirvo Elafibranor · Ipsen · 2024

Class not listed in FDA's data (1)

  • Livdelzi Seladelpar Lysine · Gilead Sciences INC · 2024

Drugs in development for primary biliary cholangitis

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • Saroglitazar MagnesiumPhase 35 trials

    Zydus Therapeutics Inc. · Primary Biliary Cholangitis, Nonalcoholic Steatohepatitis, Fibrosis

  • VolixibatSHP626Phase 22 trials

    Mirum Pharmaceuticals, Inc. · Primary Sclerosing Cholangitis, Primary Biliary Cholangitis, PBC

  • CNP-104Phase 21 trial

    COUR Pharmaceutical Development Company, Inc. · Primary Biliary Cholangitis

1 discontinued brand-name drugs whose label still names it

More on primary biliary cholangitis: recruiting trials · published research

Related in gastroenterology and liver: MASH (fatty liver disease) · Acid reflux (GERD) · Irritable bowel syndrome · Chronic constipation · Nausea and vomiting · Eosinophilic esophagitis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.